No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ABT241227C114000
- 0.93
- -0.22-19.13%
15min DelayClose Dec 23 16:00 ET
1.10High0.45Low
0.85Open1.15Pre Close59 Volume358 Open Interest114.00Strike Price5.06KTurnover16.84%IV0.54%PremiumDec 27, 2024Expiry Date0.31Intrinsic Value100Multiplier4DDays to Expiry0.62Extrinsic Value100Contract SizeAmericanOptions Type0.5758Delta0.1962Gamma115.46Leverage Ratio-0.1145Theta0.0070Rho66.48Eff Leverage0.0464Vega
Intraday
- 5D
- Daily
News
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: Agreement Will Result in Dismissal of All Pending Cases in Courts, Patent Offices Worldwide - Website
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Laboratories' (NYSE:ABT) Investors Will Be Pleased With Their Respectable 43% Return Over the Last Five Years
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135